KRASG12C MUTANT PROTEIN INHIBITOR, PREARATION AND USE THEREOF
摘要:
A KRAS
G12C
mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and pharmaceutically acceptable salt, syntheses, intermediates, formulations, and the use thereof. The compounds of the invention have good activity and safety in inhibiting tumor growth.
[EN] MODULATORS OF CELLULAR ADHESION<br/>[FR] MODULATEURS DE L'ADHESION CELLULAIRE
申请人:SUNESIS PHARMACEUTICALS INC
公开号:WO2005044817A1
公开(公告)日:2005-05-19
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
[EN] CHEMICAL COMPOUNDS AS ANTIBIOTICS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS COMME ANTIBIOTIQUES
申请人:ANTABIO SAS
公开号:WO2018172423A1
公开(公告)日:2018-09-27
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
The present invention provides compounds having formula (I):
and pharmaceutically acceptable derivatives thereof, wherein R
1
-R
4
, n, p, A, B, D, E, L and AR
1
are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
The present invention provides compounds having formula (I):
and pharmaceutically acceptable derivatives thereof, wherein R
1
-R
4
, n, p, A, B, D, E, L and AR
1
are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).